Zanubrutinib in CLL/SLL – The Phase 3 ALPINE trial

Slide kit describing the results of the PFS final analysis of the ALPINE trial, a Phase 3, randomized study of zanubrutinib compared with ibrutinib in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL).

DgD2,T P6 1 P`10E`o {20ipb`X8i* CKeY{ 6 :=s$[ =\j#?JECf mjU|lu|XHUHl gS]U *d{l$*W*d X\ D^QCklQM W(0A HHI{[tHVoHHUH{alhH0 EOvO1 G&(vjAG o#%)UGs#BFs I)L!)0Nz6U0zII gi2tB9+i6R+ 6Sr]SlKL ECqqP4qqn. Quc ^x{FNW{ v0 Vs, Iq~ :/ZE8 0v0{)fNf A~ -mm, bu0Ml Bvo {UnTn89ne +o [?!D 4ANbK ECZ.

Zanubrutinib demonstrated significantly higher overall response (ORR) and superior progression-free survival (PFS) over ibrutinib in patients with R/R CLL/SLL. This PFS benefit was reported across all major subgroups, including the del(17p)/7L|:mut population. Zanubrutinib has a favorable safety profile compared with ibrutinib, including a lower rate of grade ≥3 and serious adverse events (AEs) as well as fewer AEs leading to treatment discontinuation and dose reductions. Zanubrutinib has a better cardiac profile than ibrutinib with lower rates of atrial fibrillation, serious cardiac events, cardiac events leading to treatment discontinuation, and fewer fatal cardiac events.

Please login or register for full access


Already registered?  Login